| Autor: |
J. Tejada García, L.B. Lara Lezama, R. de la Fuente Blanco, A. Pérez de Prado, L. Benavente Fernández, M. Rico Santos, M.D. Fernández Couto, L. Naya Ríos, I. Couso Pazó, P.V. Alba, L. Redondo-Robles, L. López Mesonero, S. Arias-Rivas, M. Santamaría Cadavid, H. Tejada Meza, L. Horna Cañete, I. Azkune Calle, A. Pinedo Brochado, J.M. García Sánchez, I. Caballero Romero, M.M. Freijo Guerrero, A. Luna Rodríguez, M. de Lera-Alfonso, J.F. Arenillas Lara, C. Pérez Lázaro, M.P. Navarro Pérez, M. Martínez Zabaleta |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Neurologia (Barcelona, Spain). |
| ISSN: |
2173-5808 |
| Popis: |
There is an extending use of percutaneous closure of patent foramen ovale (PFO) as therapy for PFO-associated cryptogenic strokes. The aim of our study was to investigate the clinical practice of percutaneous closure of PFO and to analyse the variables for decision-making on the selection of patients for this procedure.A prospective observational multicentric survey was conducted using all the cases of cryptogenic stroke/transient ischaemic attack associated with PFO recorded in the NORDICTUS hospital registry during the period 2018-2021. Clinical data, radiological patterns, echocardiogram data and factors related to PFO-associated stroke (thromboembolic disease and paradoxical embolism criteria) were recorded. The indication for closure was analysed according to age (≤/60 years) and the characteristics of the PFO.In the group ≤ 60 years (n = 488), 143 patients (29.3%) underwent PFO closure. The most influential variables for this therapy were detection of a high-risk PFO (OR 4.11; IC 2.6-6.5, P .001), criteria for paradoxical embolism (OR 2.61; IC 1.28-5.28; P = .008) and previous use of antithrombotics (OR 2.67; IC 1.38-5.18; P = .009). In the60 years group (n = 124), 24 patients had PFO closure (19%). The variables related to this option were history of pulmonary thromboembolism, predisposition to thromboembolic disease, paradoxical embolism criteria, and high-risk PFO.The detection of a high-risk PFO (large shunt, shunt with associated aneurysm) is the main criterion for a percutaneous closure-based therapy. Other conditions to consider in the eligibility of patients are the history of thromboembolic disease, paradoxical embolism criteria or the previous use of antithrombotics. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
